- Home
- TBI vs FBRX Comparison
TBI vs FBRX Comparison
Compare TBI & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- FBRX
- Stock Information
- Founded
- TBI 1985
- FBRX N/A
- Country
- TBI United States
- FBRX United States
- Employees
- TBI N/A
- FBRX N/A
- Industry
- TBI Professional Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- FBRX Health Care
- Exchange
- TBI Nasdaq
- FBRX Nasdaq
- Market Cap
- TBI 169.2M
- FBRX 154.5M
- IPO Year
- TBI 1996
- FBRX N/A
- Fundamental
- Price
- TBI $6.19
- FBRX $11.96
- Analyst Decision
- TBI Buy
- FBRX Strong Buy
- Analyst Count
- TBI 1
- FBRX 3
- Target Price
- TBI $8.00
- FBRX $68.00
- AVG Volume (30 Days)
- TBI 110.3K
- FBRX 79.4K
- Earning Date
- TBI 11-03-2025
- FBRX 11-13-2025
- Dividend Yield
- TBI N/A
- FBRX N/A
- EPS Growth
- TBI N/A
- FBRX N/A
- EPS
- TBI N/A
- FBRX N/A
- Revenue
- TBI $1,534,863,000.00
- FBRX N/A
- Revenue This Year
- TBI $2.21
- FBRX N/A
- Revenue Next Year
- TBI $6.18
- FBRX N/A
- P/E Ratio
- TBI N/A
- FBRX N/A
- Revenue Growth
- TBI N/A
- FBRX N/A
- 52 Week Low
- TBI $3.45
- FBRX $4.11
- 52 Week High
- TBI $9.05
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- TBI 53.53
- FBRX 59.36
- Support Level
- TBI $5.41
- FBRX $10.11
- Resistance Level
- TBI $5.96
- FBRX $11.57
- Average True Range (ATR)
- TBI 0.29
- FBRX 0.84
- MACD
- TBI 0.07
- FBRX 0.09
- Stochastic Oscillator
- TBI 64.46
- FBRX 78.22
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).